Enovis (ENOV) Current Deferred Revenue (2010 - 2016)
Enovis (ENOV) reported Current Deferred Revenue of $151.0 million for Q4 2016, down 22.57% year-over-year from $195.0 million in Q1 2016, and down 22.57% on a QoQ basis from $195.0 million in Q4 2015.
Enovis (ENOV) has 4 years of Current Deferred Revenue data on file, last reported at $151.0 million in Q4 2016.
- Quarterly Current Deferred Revenue fell 22.57% year-over-year to $151.0 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $151.0 million (down 22.57% YoY) and the FY2016 annual result came in at $151.0 million, down 22.57% from the prior year.
- Current Deferred Revenue eased to $151.0 million in Q4 2016 per ENOV's latest filing, from $195.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $195.0 million in Q4 2015 and bottomed at $151.0 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Enovis | 1.25 Bn | 1.22 Bn | 365.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 151.02 Mn |
| Dec 31, 2015 | 195.04 Mn |
| Dec 31, 2011 | 14.70 Mn |
| Sep 30, 2011 | 13.58 Mn |
| Jul 1, 2011 | 22.19 Mn |
| Dec 31, 2010 | 17.25 Mn |